A new analog of 1,25-(OH)2D3, 19-NOR-1,25-(OH)2D2, suppresses serum PTH and parathyroid gland growth in uremic rats without elevation of intestinal vitamin D receptor content

American Journal of Kidney Diseases

Volumn 30, Issue 1, 1997, Pages 105-112

  Takahashi, Fumiaki ^a   Finch, Jane L ^a   Denda, Masashi ^a   Dusso, Adriana S ^a   Brown, Alex J ^a   Slatopolsky, Eduardo ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Calcitriol; Parathyroid hormone; Uremia; Vitamin D analogs

Indexed keywords

1,25 DIHYDROXYERGOCALCIFEROL; 19 NOR 1,25 DIHYDROXYERGOCALCIFEROL; CALCITRIOL; CALCITRIOL DERIVATIVE; UNCLASSIFIED DRUG; VITAMIN D RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG SELECTIVITY; FEMALE; HEMODIALYSIS; HYPERCALCEMIA; HYPERPHOSPHATEMIA; INTRAPERITONEAL DRUG ADMINISTRATION; NONHUMAN; PARATHYROID HORMONE BLOOD LEVEL; PARATHYROID HORMONE RELEASE; RAT; SECONDARY HYPERPARATHYROIDISM; UREMIA;

EID: 0030837556     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0272-6386(97)90571-0     Document Type: Article

References (51)

1. Slatopolsky E, Weerts C, Thielan J, Horst R, Harter H, Martin KJ: Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxycholecalciferol in uremic patients. J Clin Invest 74:2136-2143, 1984
2. Delmez JA, Tindira C, Grooms P, Dusso A, Windus DW, Slatopolsky E: Parathyroid hormone suppression by intravenous 1,25-dihydroxyvitamin D: A role for increased sensitivity to calcium. J Clin Invest 83:1349-1355, 1989
3. Andress DL, Keith MD, Norris C, Coburn JW, Slatopolsky E, Sherrard DJ: Intravenous calcitriol in the treatment of refractory osteitis fibrosa of chronic renal failure. N Engl J Med 321:274-279, 1989
4. Gallieni M, Brancaccio D, Padovese P, Rolla D, Bedani P, Colantonio G, Bronzieri C, Bagni B, Tarolo G: Low-dose intravenous calcitriol treatment of secondary hyperparathyroidism in hemodialysis patients. Kidney Int 42:1191-1198, 1992
5. Cannella G, Bonucci E, Rolla D, Ballanti P, Moriero E, DeGrandi R, Augeri C, Claudiani F, DiMaio G: Evidence of healing of secondary hyperparathyroidism in chronically hemodialyzed uremic patients treated with long-term intravenous calcitriol. Kidney Int 46:1124-1132, 1994
6. Slatopolsky E, Weerts C, Lopez-Hilker S, Norwood K, Zink M, Windus D, Delmez J: Calcium carbonate as a phosphate binder in patients with chronic renal failure undergoing dialysis. N Engl J Med 315:157-161, 1986
7. Haussler MR, Jurutka PW, Hsieh JC, Thompson PD, Selznick SH, Haussler CA, Whitfield GK: New understanding of the molecular mechanism of receptor-mediated genomic actions of the vitamin D hormone. Bone 17:33S-38S, 1995 (suppl)
8. Ross TK, Darwish HM, DeLuca HF: Molecular biology of vitamin D action. Vitamins Hormones 49:281-326, 1994
9. Bikle DD: Clinical counterpoint: Vitamin D: New actions, new analogs, new therapeutic potential. Endocrine Rev 13:765-784, 1992
10. Brown AJ, Dusso A, Slatopolsky E: Selective vitamin D analogs and their therapeutic applications. Semin Nephrol 14:156-174, 1994
11. Norman AW: The vitamin D endocrine system: Manipulation of structure-function relationships to provide opportunities for development of new cancer chemopreventive and immunosuppressive agents. J Cell Biochem 22:S218-S225, 1995 (suppl)
12. 3: Preferential activity in inducing differentiation of human leukemia cells HL-60 in vitro. Proc Natl Acad Sci 84:2610-2614, 1987
13. Binderup L, Bramm E: Effects of a novel vitamin D analogue MC903 on cell proliferation and differentiation in vitro and on calcium metabolism in vivo. Biochem Pharmacol 37:889-895, 1988
14. Zhou JY, Norman AW, Lubbert M, Collins ED, Uskokovic MR, Koeffler HP: Novel vitamin D analogs that modulate leukemic cell growth and differentiation with little effect on either intestinal calcium absorption or bone calcium mobilization. Blood 74:82-93, 1989
15. 3 with an oxygen atom in their side chain. Biochem Int 19:1143-1149, 1989
16. 3 analogues on the proliferation and differentiation of cultured human keratinocytes, calcium metabolism and the differentiation of human HL-60 cells. J Nutr Biochem 4:49-57, 1993
17. 3, inhibits the growth of human breast cancer in vitro and in vivo without causing hypercalcemia. Endocrinology 129:832-837, 1991
18. 3, a potent angiogenesis inhibitor, on rat mammary tumors induced by 7,12-dimethylbenz[a]-anthracene. Anti-cancer Drugs 2:475-480, 1991
19. Colston KW, Chander SK, Mackay AG, Coombes RC: Effects of synthetic vitamin D analogues on breast cancer cell proliferation in vivo and in vitro. Biochem Pharmacol 44:693-702, 1992
20. 3, is a potent modulator of in vivo immunoregulating activity without inducing hypercalcemia in mice. Endocrinology 124:2645-2647, 1989
21. Brown AJ, Ritter CR, Finch JL, Morrissey J, Martin KJ, Murayama E, Nishii Y, Slatopolsky E: The noncalcemic analogue of vitamin D, 22-oxacalcitriol, suppresses parathyroid hormone synthesis and secretion. J Clin Invest 84:728-732, 1989
22. 2, suppresses parathyroid hormone secretion in uremic rats in the absence of hypercalcemia. Am J Kidney Dis 26:852-860, 1995
23. Dusso AS, Negrea L, Gunawardhana S, Lopez-Hilker S, Finch J, Mori T, Nishii Y, Slatopolsky E, Brown AJ: On the mechanisms for the selective action of vitamin D analogs. Endocrinology 128:1687-1692, 1991
24. Brown AJ, Finch J, Grieff M, Ritter C, Kubodera N, Nishii Y, Slatopolsky E: The mechanism for the disparate actions of calcitriol and 22-oxacalcitriol in the intestine. Endocrinology 133:1158-1164, 1993
25. 3, in rats. J Biochem 115:373-380, 1994
26. Hollis BW: Assay of circulating 1,25-dihydroxyvitamin D metabolites involving a novel single extraction and purification procedure. Clin Chem 32:2060-2063, 1986
27. Reinhardt TA, Horst RL, Orf W, Hollis BW: A microassay for 1,25-dihydroxyvitamin D not requiring high performance liquid chromatography: Application to clinical studies. J Clin Endocrinol Metab 58:91-98, 1984
28. Slatopolsky E, Finch J, Denda M, Ritter C, Zhong M, Dusso A, MacDonald PN, Brown AJ: Phosphorus restriction prevents parathyroid gland growth: High phosphorus directly stimulates PTH secretion in vitro. J Clin Invest 97:2534-2540, 1996
29. Fukagawa M, Kaname S, Igarashi T, Ogata E, Kurokawa K: Regulation of parathyroid hormone synthesis in chronic renal failure in rats. Kidney Int 39:874-881, 1991
30. Bover J, Rodriguez M, Trinidad P, Jara A, Martinez ME, Machado L, Llach F, Felsenfeld AJ: Factors in the development of secondary hyperparathyroidism during graded renal failure in the rat. Kidney Int 45:953-961, 1994
31. Tallon S, Berdud I, Hernandez A, Concepcion MT, Almaden Y, Torres A, Martin-Malo A, Felsenfeld AJ, Aljama P, Rodriguez M: Relative effects of PTH and dietary phosphorus on calcitriol production in normal and azotemic rats. Kidney Int 49:1441-1446, 1996
32. 3 in response to parathyroid hormone in patients with incipient renal failure. Nephron 57:314-318, 1991
33. Prince RL, Hutchison BG, Dick L: The regulation of calcitriol by parathyroid hormone and absorbed dietary phosphorus in subjects with moderate chronic renal failure. Metabolism 42:834-838, 1993
34. Naveh-Many T, Rahamimov R, Livni N, Silver J: Parathyroid cell proliferation in normal and chronic renal failure rats: The effects of calcium, phosphate, and vitamin D. J Clin Invest 96:1786-1793, 1995
35. 3 inhibits parathyroid cell proliferation in experimental uremia. Kidney Int 35:1049-1056, 1989
36. Dusso AS, Negrea L, Finch J, Kamimura S, Lopez-Hilker S, Mori T, Nishii Y, Brown A, Slatopolsky E: The effect of 22-oxacalcitriol on serum calcitriol. Endocrinology 130:3129-3134, 1992
37. Grieff M, Dusso A, Mori T, Nishii Y, Slatopolsky E, Brown AJ: 22-Oxacalcitriol suppresses 25-hydroxycholecalciferol-1α-hydroxylase in rat kidney. Biochem Biophys Res Commun 185:191-196, 1992
38. Okano T, Tsugawa N, Murano M, Masuda S, Takeuchi A, Kobayashi T, Sato K, Nishii Y: ED-71 increases bone mineral density, mineral contents and mechanical strength in ovariectomized rats. J Bone Min Res 7(S1):S156, 1992 (suppl 1; abstr 255)
39. Akeno N, Saikatsu S, Kimura S, Horiuchi N: Induction of vitamin D 24-hydroxylase messenger RNA and activity by 22-oxacalcitriol in mouse kidney and duodenum. Biochem Pharmacol 48:2081-2090, 1994
40. 3 in T-47D human breast cancer cells. J Steroid Biochem Mol Biol 54:147-153, 1995
41. 3. Mol Endocrinol 7:1307-1312, 1993
42. Johnson JA, Kumar R: Renal and intestinal calcium transport: Roles of vitamin D and vitamin D-dependent calcium binding proteins. Semin Nephrol 14:119-128, 1994
43. 3. J Nutr Sci Vitaminol 35:529-533, 1989
44. 3 by normal human peripheral monocytes. Endocrinology 133:2719-2723, 1993
45. Bikle DD, Abe-Hashimoto J, Su MJ, Felt S, Gibson DFC, Pillai S: 22-oxa calcitriol is a less potent regulator of keratinocyte proliferation and differentiation due to decreased cellular uptake and enhanced catabolism. J Invest Dermatol 105:693-698, 1995
46. 3 analogues: A novel class of potent regulators of cell growth and immune responses. Biochem Pharmacol 42:1569-1575, 1991
47. 3, exerts immunosuppressive activity equal to its parent without causing hypercalcemia in vivo. Endocrinology 135:2818-2821, 1994
48. 3 in kidney: Influence of structural modification of D-ring on side chain metabolism. Bioorg Med Chem Lett 3:1879-1884, 1993
49. 3 analog structure-function assessment of the rapid stimulation of intestinal calcium absorption (transcaltachia). J Bone Miner Res 7:457-463, 1992
50. 3: Potential relation of a plasmalemmal receptor to the acute enhancement of intestinal calcium transport in chick. J Nutr 125:1695S-1698S, 1995 (suppl)
51. 3. Mol Endocrinol 9:1814-1824, 1995